Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | CDC25B | P30305 | 1/20 | 0.67 |
| ▸ | BCL2 | P10415 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236156 | 1.00 | MEN1 (0.67) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL30327427 | 1.00 | MEN1 (0.67) | MEN1KMT2ACDC25BBCL2MCL1 | |
| Hydrochloric Acid SCHEMBL10789329 | 0.97 | MEN1 (0.63) | MEN1KMT2ACDC25BBCL2MCL1 | |
| Hydrochloric Acid SCHEMBL10785532 | 0.97 | MEN1 (0.63) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL652915 | 0.95 | MEN1 (0.60) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL347152 | 0.95 | MEN1 (0.60) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL29440306 | 0.95 | MEN1 (0.60) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL29634247 | 0.95 | MEN1 (0.60) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL354514 | 0.94 | MEN1 (0.56) | MEN1KMT2ACDC25BBCL2MCL1 | |
| SCHEMBL29364188 | 0.94 | MEN1 (0.56) | MEN1KMT2ACDC25BBCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240085670-A1 | METHODS OF MAKING A LOW-COST MINIATURE ACCOMMODATING OPTICAL IMAGING SYSTEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | claimed |
| WO-2025238187-A1 | IMMUNOCONJUGATES TARGETING L1-CAM | CIS BIOPHARMA AG (CH) | 2025-11-20 | — | — | WO | disclosed |
| EP-4638428-A1 | HETEROCYCLIC ACRYLIC ACID DERIVATIVES AS MONOMERS FOR THE SYNTHESIS OF POLYMERS FOR USE IN ION EXCHANGE ARTICLES | Solventum Intellectual Properties Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250295791-A1 | COLLAGEN-CONTAINING CURABLE FORMULATIONS | COLLPLANT LTD. (IL) | 2025-09-25 | — | — | US | disclosed |
| EP-4618993-A1 | LURBINECTEDIN AND DOXORUBICIN COMBINATION | Pharma Mar S.A. (ES) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615580-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS Biopharma AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4598985-A1 | ANION EXCHANGE SEPARATION ARTICLE, METHODS OF MAKING, AND METHODS OF USING | Solventum Intellectual Properties Company (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4572776-A2 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | Artiva Biotherapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-118647402-A | Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma | 健玛保 | 2024-09-13 | — | — | CN | disclosed |
| EP-4422707-A1 | COLLAGEN-CONTAINING CURABLE FORMULATIONS | CollPlant Ltd. (IL) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024100200-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS PHARMA AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024074906-A1 | ANION EXCHANGE SEPARATION ARTICLE, METHODS OF MAKING, AND METHODS OF USING | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240085670-A1 | METHODS OF MAKING A LOW-COST MINIATURE ACCOMMODATING OPTICAL IMAGING SYSTEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| WO-2024040135-A2 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4319772-A1 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | Artiva Biotherapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024015316-A1 | COATED FLEXIBLE ARTICLES WITH ANTI-ICING SURFACE | PHAZEBREAK COATINGS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11769881-B1 | Ion-based electrochemical cell formulations and methods of preparation thereof | ORUGANTY SRIGOURI (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023073711-A1 | COLLAGEN-CONTAINING CURABLE FORMULATIONS | COLLPLANT LTD. (IL) | 2023-05-04 | — | — | WO | disclosed |
| EP-4136070-A1 | MONOMERS, POLYMERS, AND ARTICLES FOR BIOMATERIAL CAPTURE | 3M Innovative Properties Company (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022216837-A1 | TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295791-A1 | COLLAGEN-CONTAINING CURABLE FORMULATIONS | COL1A1, COL14A1, COL2A1 | MEN1 2848/4885KMT2A 1961/4885CDC25B 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.